We also classified patients with HR-positive/HER2-negative breast cancer according to menopausal status, and found that only postmenopausal patients showed significantly better RFS in the good control group compared with the poor control group (p = 0.014, log-rank) (Fig. 3). Here, ERBB2 is linked to breast cancer.